Source:http://linkedlifedata.com/resource/pubmed/id/10080574
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1999-3-23
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0002-953X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
156
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
495
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10080574-Adult,
pubmed-meshheading:10080574-Humans,
pubmed-meshheading:10080574-Male,
pubmed-meshheading:10080574-Severity of Illness Index,
pubmed-meshheading:10080574-Tetrahydrocannabinol,
pubmed-meshheading:10080574-Tourette Syndrome,
pubmed-meshheading:10080574-Treatment Outcome
|
pubmed:year |
1999
|
pubmed:articleTitle |
Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol.
|
pubmed:publicationType |
Letter,
Clinical Trial,
Case Reports
|